Immutep Announces Improving Data from the Phase II TACTI-002 Study
Presented at ASCO 2020 Annual Meeting First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR) Progression free survival (PFS) …